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Abstract
Background: Post-transcriptional gene silencing (PTGS) by short interfering RNA has opened up
new directions in the phenotypic mutation of cellular genes. However, its efficacy on non-nuclear
genes and its effect on the interferon pathway remain unexplored. Since directed mutation of RNA
genomes is not possible through conventional mutagenesis, we have tested sequence-specific 21-
nucleotide long double-stranded RNAs (dsRNAs) for their ability to silence cytoplasmic RNA
genomes.
Results: Short dsRNAs were generated against specific mRNAs of respiratory syncytial virus, a
nonsegmented negative-stranded RNA virus with a cytoplasmic life cycle. At nanomolar
concentrations, the dsRNAs specifically abrogated expression of the corresponding viral proteins,
and produced the expected mutant phenotype ex vivo. The dsRNAs did not induce an interferon
response, and did not inhibit cellular gene expression. The ablation of the viral proteins correlated
with the loss of the specific mRNAs. In contrast, viral genomic and antigenomic RNA, which are
encapsidated, were not directly affected.
Conclusions: Synthetic inhibitory dsRNAs are effective in specific silencing of RNA genomes that
are exclusively cytoplasmic and transcribed by RNA-dependent RNA polymerases. RNA-directed
RNA gene silencing does not require cloning, expression, and mutagenesis of viral cDNA, and thus,
will allow the generation of phenotypic null mutants of specific RNA viral genes under normal
infection conditions and at any point in the infection cycle. This will, for the first time, permit
functional genomic studies, attenuated infections, reverse genetic analysis, and studies of host-virus
signaling pathways using a wild type RNA virus, unencumbered by any superinfecting virus.
Background
Over the last decade, RNA interference (RNAi), mediated
by short interfering double-stranded RNA molecules (siR-
NA or dsRNA), has been gradually recognized as a major
mechanism of post-transcriptional gene silencing (PTGS)
in species as diverse as plants, Drosophila, and C. ele-
gans[1]. Recently, 21-nucleotide long dsRNA molecules
corresponding to specific mRNA sequences, when intro-
duced into mammalian cells in culture, have been shown
to be highly effective in degrading the cognate mRNAs
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and thus abrogating the expression of the corresponding
proteins [2]. Although the exact mechanism of PTGS is
currently unknown and is an area of intense research, the
successful use of this phenomenon in cultured mammali-
an cells has raised the exciting prospect that it can be used
as a simple strategy for phenotypic ablation of mammali-
an gene function ex vivo without the time-consuming and
expensive construction of transgenic animals.
So far, the genes targeted for siRNA-mediated PTGS have
been cellular in origin and thus, the mRNAs were tran-
scribed in the nucleus by cellular DNA-dependent RNA
polymerase. In contrast, the vast majority of RNA genom-
es are transcribed exclusively in the cytoplasm. For exam-
ple, transcription of RNA viral genomes, with the
exception of retroviral RNA, is catalyzed by a virally en-
coded RNA-dependent RNA polymerase (RdRP) [3]. It re-
mains untested whether the siRNA-mediated PTGS will
work on mRNAs that never went through the nucleus. In-
terestingly, because of the potency of siRNA in some or-
ganisms, it has been proposed that they may be replicated
by a cellular RdRP activity, although this has been debated
[4]. Furthermore, since dsRNA is known to be a potent in-
ducer of the interferon pathway [5,6], it is important to
know whether this also occurs in cells in which antisense
dsRNA has been introduced.
To answer these questions, we have used a nonsegmented
negative-strand RNA (NNR) virus as a test target for RNA-
mediated inhibition. We reasoned that, if successful, our
studies would additionally contribute a reliable and sim-
ple technology for specific gene silencing in cytoplasmic
RNA viruses. Traditionally, structure-function analyses of
RNA genomes, including those of RNA viruses, have relied
on spontaneous mutants found in natural isolates or
chemically mutagenized stocks [7]. Mutations in either
case are essentially unpredictable and must be mapped by
elaborate techniques such as classical complementation
analyses or direct sequencing of the genome. Since con-
ventional site-directed mutagenesis requires a DNA tem-
plate, direct mutational analysis of selected RNA genes is
not an option. These obstacles have been largely circum-
vented by the use of cloned viral cDNA that is then altered
by standard DNA-based site-directed mutagenesis proce-
dures [8,9]. Originally designed for influenza virus mini-
genomes [10], such cDNA-based "reverse genetics"
strategy has been adopted in a large number of NNR virus-
es, including vesicular stomatitis virus (VSV), respiratory
syncytial virus (RSV), and measles, to name a few [11–14].
Recently, extension of this approach has resulted in the
cloning of full-length viral cDNA capable of producing in-
fectious recombinant virus particles upon transcription.
Despite its revolutionary effect on RNA viral reverse genet-
ics, however, the cDNA-based strategy is not without lim-
itations. First, as implied above, cloning and recombinant
expression of the viral genomic RNA and all the viral pro-
teins in the right proportion constitute a long and arduous
task, daunting to an average laboratory. The problem is
particularly acute for NNR viruses, which have large RNA
genomes [8,9]. The 10–15 kb long RNA genomes of these
viruses require specific sequences at the 5' and 3' termini
for transcription and replication, and must be properly
encapsidated by the nucleocapsid protein (N) in order to
be recognized by the viral RdRP [15,16]. Thus, any recom-
binant technology must be able to faithfully reproduce
these features of the genome. Moreover, the functional vi-
ral RdRP, as detailed later for RSV, is a complex holoen-
zyme composed of viral as well as cellular proteins [17–
23]. Second, many NNR viral genomes and proteins are
currently expressed from vaccinia-based cDNA clones,
which generally requires superinfection by vaccinia virus
[22,23]. Unfortunately, vaccinia virus itself is a major
modulator of cellular signaling, including MAP kinase
pathways and the actin cytoskeleton [24–26]. It is, there-
fore, virtually impossible to study the interaction between
cellular signaling pathways and NNR viruses in cells that
are also superinfected by vaccinia virus [24–26]. Third,
mutations in the recombinant DNA are "permanent", and
thus, the mutational phenotype cannot be switched on at
pre-determined time points in infection. For example, if a
viral gene product has essential roles both early and late
in infection, its mutational inactivation will fail to reveal
the late function, since the mutant virus will never pro-
ceed beyond the early stage.
A member of the Paramyxoviridae family, RSV is a major
causative agent of childhood respiratory disease and asth-
ma [27]. Pediatric RSV disease claims about a million lives
annually, and no reliable antiviral or vaccine currently ex-
ists [27,28]. A need to understand the molecular genetics
of the virus and the function of the various gene products
has thus been appreciated. Since our laboratory is interest-
ed in deciphering the temporal signaling pathways in
host-RSV interaction and the role of RSV gene products in
the process, we have sought potential alternatives to the
cDNA-based approach that might allow us to study the ef-
fect of functional loss of a specific RSV gene product dur-
ing the course of a standard virus infection in cell culture.
Using two different RSV gene mRNAs as targets, and an-
other NNR virus (VSV) as well as cellular mRNAs as con-
trols, we show that synthetic dsRNA molecules are highly
efficient and specific silencers of cytoplasmic RNA viral
gene expression. We also provide the first direct evidence
that the 21-nt long dsRNAs do not activate a general inter-
feron response. Our results thus offer a mechanism of spe-
cific and direct ablation of RNA-based gene expression
and a quicker and simpler alternative to cDNA-based re-
verse genetics of RNA viruses.BMC Microbiology 2001, 1 http://www.biomedcentral.com/1471-2180/1/34
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Results
Ablation of viral gene expression by dsRNA against RSV P 
mRNA
The RNA genome of RSV is about 15 kb long and contains
11 documented protein-coding genes [13]. Three viral
proteins are minimally required to reconstitute the func-
tional transcription complex of NNR viruses [3]: the nu-
cleocapsid protein (N) that wraps the negative-strand
genome RNA and its full-length complement, the posi-
tive-strand antigenome RNA, thus converting them into
highly nuclease-resistant, chromatin-like templates; the
large protein (L), which is the major subunit of the RdRP;
and the phosphoprotein (P), which is the smaller subunit
of RdRP and an essential transcription factor of L [19–22].
In RSV, optimal transcription, although not replication,
additionally requires the transcription antitermination
protein M2-1 [13]. In addition, cellular actin, and to a
lesser extent, profilin, are also required for viral transcrip-
tion [17,18].
The overall steps of a NNR viral macromolecular synthesis
in the infected cell are relevant for this paper, and are
briefly described here [3]. The L protein is believed to en-
code the basic RNA polymerization function, and binds to
the viral promoter at the 3' end of the genomic RNA to in-
itiate transcription. However, the P protein is essential for
the RdRP holoenzyme to exit the promoter and to form a
closed complex that is capable of sustained elongation
[20]. The preformed RdRP brought in by the infecting vi-
ral nucleocapsids catalyzes the first rounds of transcrip-
tion, known as primary transcription. In its "transcription
mode", the viral RdRP starts and stops at the beginning
and end, respectively, of each viral gene, and this results in
the synthesis of individual gene mRNAs. Unlike the full-
length genomic and antigenomic RNA, the mRNAs are 5'-
capped, 3'-polyadenylated, and do not bind N protein.
Translation of these mRNAs results in de novo synthesis of
viral proteins. The availability of large quantities of N pro-
tein then allows encapsidation of nascent leader RNA by
N. This leads to the switching of the RdRP to the "replica-
tion mode", resulting in the synthesis of full-length, en-
capsidated anti-genomic RNA, which is in turn replicated
into more genomic RNA [15]. Thus, the very requirement
of N for replication ensures that all full-length genomic
and antigenomic RNA are wrapped with N protein, i.e.,
encapsidated [15]. The new pool of replicated genomic
RNA serves as templates for secondary transcription. It
should be obvious from the foregoing that the de novo
macromolecular synthesis accounts for the major burst of
viral protein and RNA in the infected cell. Specifically, if
the de novo synthesis of the essential subunits of viral
RdRP – such as L or P – is inhibited, it will abolish the
bulk of viral transcription and replication, and hence, vi-
ral translation [3].
To test the effectiveness of the anti-P dsRNA, we transfect-
ed the dsRNA into A549 cells, and infected the cells with
RSV. Subsequently, the amount of intracellular P protein
was directly monitored by immunoblot analysis using
anti-P antibody. Results presented in Fig. 1 show a nearly
90% reduction of P protein using as little as 10 nM dsR-
NA. Although we have not tested lower amounts of dsR-
NA for P, the severe loss of P protein at 10 nM dsRNA and
only a slightly greater loss with higher dsRNA concentra-
tions (Fig. 1) suggest that it may be possible to cause sub-
stantial ablation of P protein at dsRNA concentrations
even below 10 nM.
The phenotypic effect of loss of P was further examined by
measuring progeny viral titer, overall viral protein synthe-
sis, and syncytium formation, as described under Materi-
als and Methods. Yield of progeny virus in 20 nM dsRNA-
treated cells was found to be reduced by 10 fold, and was
reduced by at least 104 fold at 100 and 300 nM dsRNA
(data not shown). De novo viral protein synthesis was
measured by metabolic labeling with S35-Met/Cys fol-
lowed by immunoprecipitation. As shown in Fig. 1, all vi-
ral proteins detectable in the precipitate were drastically
diminished in the dsRNA-treated cells, as would be ex-
pected in the event of a loss of the P protein. The inhibi-
tion of viral growth was further reflected in the essentially
complete loss of cell fusion (syncytia) in the treated cells
(Fig. 2). In fact, the RSV-infected anti-P dsRNA-treated
cells were morphologically indistinguishable from con-
trol uninfected ones even at 5 days post-infection, which
was the longest time period for which they were observed.
The presence of equal amounts of actin in all the samples
confirmed that the observed inhibition of viral proteins is
not due to a general degradation of proteins.
The specificity of dsRNA activity was further tested by us-
ing a dsRNA against cellular lamin A/C that was earlier
shown to specifically abrogate lamin A/C synthesis in a
variety of cultured cell lines [2]. As shown in Fig. 1 (lane
'La'), the anti-lamin dsRNA, while abrogating lamin pro-
tein (data not shown) had no effect on RSV protein syn-
thesis. Furthermore, a mismatched anti-P dsRNA in which
the lowercase A-U base pair (see the dsRNA sequences in
Materials and Methods) was altered to a G-C pair also
failed to inhibit viral translation (data not shown), con-
firming that a perfect match is needed for the dsRNA ef-
fect, hence its extreme specificity of action.
Lack of syncytium in RSV-infected cells treated with anti-F 
dsRNA
Fusion of the infected cells is a hallmark of all Paramyxo-
viruses including RSV (as also in some other viruses, such
as HIV), and the resultant mass of fused cells is referred as
a syncytium, from which respiratory syncytial virus de-
rives its middle name. The fusion protein F is by far theBMC Microbiology 2001, 1 http://www.biomedcentral.com/1471-2180/1/34
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most important viral glycoprotein that is central to the cell
fusion activity [29]. Since the P and F proteins have such
diverse roles in viral life cycle, we decided to investigate
the effect of dsRNA on F as a second test gene, and also to
compare and contrast the two respective phenotypes.
First, to test the effectiveness of the anti-F dsRNA intracel-
lularly, we probed the infected cell monolayer with anti-F
antibody by indirect immunofluorescence (Fig. 3). Re-
sults clearly demonstrated the abundant synthesis of F
protein as cytoplasmic fluorescence in cells that were not
treated with dsRNA; the nuclei of the same cells could be
visualized by staining with DAPI. In contrast, cells treated
with just 3 nM anti-F dsRNA showed a substantial loss of
F stain. At 20 nM dsRNA, F protein was undetectable.
Second, immunoblot analysis (Fig. 4, top panel) revealed
that anti-F dsRNA, at concentrations as low as 20 nM, pro-
duced a severe reduction in F protein levels. Again, no ef-
fect was seen on cellular profilin, ruling out a general
protein loss. The anti-F dsRNA also had no effect on P pro-
tein levels, suggesting that such dsRNAs do not activate a
general antiviral response that might abrogate all viral
mRNA translation. This was further corroborated by the
direct measurement of de novo viral protein synthesis by
metabolic labeling (Fig. 4, bottom panel). Results showed
that the synthesis of F only was affected while all other vi-
ral proteins were translated in normal amounts, which is
in agreement with the notion that F has little or no role in
intracellular viral macromolecular synthesis.
Finally, the phenotype of F protein loss was tested by ex-
amining syncytia formation, and as presented in Fig. 2, no
syncytia could be discerned in anti-F dsRNA-treated cells
(Panel B). However, a cytopathic effect was still visible,
which is most likely the result of intracellular replication
of the virus. This demonstrates an interesting contrast
with the anti-P dsRNA (Panel C), which inhibited all viral
gene expression, and therefore, the resultant monolayer
exhibited essentially the same appearance as the uninfect-
ed one (Panel D).
Direct measurement of intracellular F mRNA by semi-
quantitative RT-PCR showed a nearly 15-fold loss caused
by anti-F dsRNA (Fig. 5, top panel). Similar RT-PCR of vi-
ral genomic RNA, viral P mRNA, or cellular actin mRNA
revealed essentially no reduction, suggesting that the dsR-
NA did not activate a general antiviral response, and did
not directly target genomic RNA. Together, these results
directly demonstrate that the dsRNAs promote ablation of
the specific mRNA target, which most likely underlies the
loss of the respective proteins.
Figure 1
Ablation of RSV P protein by anti-P dsRNA. Transfection of
A549 cells with 0 (no dsRNA), 10, 100, or 300 nM dsRNA
and infection with RSV were carried out as described under
Materials and Methods. Lane 'U' indicates control, uninfected
cells. Top: Immunoblot (Western) of total cell extracts was
performed with either rabbit anti-P or monoclonal anti-actin
antibody (Boehringer-Mannheim), as indicated. Bottom: Viral
protein synthesis in dsRNA-treated cells was measured by
standard immunoprecipitation procedures as described pre-
viously [17]. Infected A549 cells (or uninfected control, lane
'U') were metabolically labeled with 35S-(methionine plus
cysteine) at 18 h post-infection, followed by lysis of the cells,
precipitation with anti-RSV antibody, and analysis of the
labeled proteins by SDS-PAGE and autoradiography. 'La' rep-
resents treatment with 100 nM anti-lamin A/C dsRNA. The
different viral protein bands are so indicated.
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Anti-RSV dsRNAs do not activate an interferon response
As mentioned before, cytoplasmic dsRNA can trigger a se-
ries of signaling reactions that lead to interferon (IFN)
synthesis [5,6]. In the "interferon response", dsRNA mol-
ecules activate protein kinase PKR and 2',5'-oligonucle-
otide synthetase. One of the effects of PKR is to
phosphorylate the α  subunit of the general translation in-
itiation factor eIF-2, which constitutes a major mecha-
nism for global translation arrest. The 2', 5'-
oligonucleotide synthetase activates RNase L that in turn
catalyses non-specific degradation of mRNA. Since NNR
viruses co-opt the cellular translation machinery, the in-
terferon response thus causes severe inhibition of viral
translation. Interestingly, the IFN response requires long
dsRNA [5,6], and it has been conjectured that the im-
proved specificity of the 21-nucleotide long dsRNA in cul-
tured mammalian cells is probably due to their inability
to activate the IFN response [2]. We provide several lines
of direct and indirect evidence that the dsRNAs described
here did not activate a general IFN response. First, the in-
Figure 2
Effect of dsRNA on the cell fusion activity of RSV. A549 monolayers were transfected with 20 nM of anti-P or anti-F dsRNA
and infected with RSV as described under Materials and Methods. At 40 h p.i., the monolayers were examined under a Nikon
TS100F phase-contrast microscope at 40×  magnification and digitally photographed with a Nikon Coolpix 995 camera. Note
the syncytia in 'A', cytopathic effect without syncytia in 'B', and monolayers that appear unaffected and identical in 'C' and 'D'.
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RSV only
Uninfected
RSV + P-dsRNA
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B
C
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Figure 3
Ablation of RSV F by anti-F dsRNA. Anti-F dsRNA, RSV infection, and immunostaining of A549 monolayer were performed as
described under Materials and Methods. Right panel shows the nuclear staining of the same cells using DAPI (Blue). Note the
substantial reduction of F (Green) with as low as 3 nM anti-F dsRNA, and reduction to background levels by 20 nM dsRNA.
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Figure 4
Specificity of anti-F dsRNA. Experiments were done essen-
tially as described for Fig. 2. A549 cells were transfected with
the indicated amounts of anti-F dsRNA followed by infection
by RSV as described under Materials and Methods. Top:
Immunoblot of total cell extracts to detect RSV F, RSV P, and
profilin; Bottom: Autoradiograph showing immunoprecipi-
tated metabolically 35S-labeled RSV proteins. 'U' represents
uninfected cells. Note the specific loss of F protein, but no
effect on other proteins.
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Figure 5
Induction of target mRNA degradation but not interferon
response by dsRNA. Panel A: Semi-quantitative RT-PCR to
measure the indicated RSV gene mRNA and genomic RNA in
A549 cells were performed as described under Materials and
Methods. Where indicated (labeled '+'), anti-F dsRNA was
used at a concentration of 20 nM. PCR samples were taken
at the end of the number of cycles indicated on top (20, 22,
24, and 26). Actin mRNA was also quantitated as a control.
Note that in dsRNA-untreated cells (labeled '-') the F band is
visible even at 20 cycles, whereas in the treated cells, appear-
ance of a comparable intensity required 4 additional PCR
cycles, i.e., 16-fold more amplification. Panel B: Assay of eIF-
2α  phosphorylation. Metabolic 32P-labeling and immunopre-
cipitation (IP) analysis of eIF-2 have been described in Materi-
als and Methods. An autoradiograph of the gel is shown. The
cells were treated with no RNA (lane C), 100 nM thapsi-
gargin (lane 1), 100 nM A23178 (lane 2), 50 nM anti-P dsRNA
(lane 3), or 50 nM anti-F dsRNA (lane 4). Note the increased
phosphorylation of eIF-2 in lanes 1 and 2 only. The immunob-
lot (IB) shows that the total amount of eIF-2α  protein was
not affected by the treatments.
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hibitory effect of each dsRNA was gene-specific (Figs. 1, 2,
4). Second, growth of VSV is known to be highly sensitive
to IFN, however, its replication in A549 cells was not af-
fected by any of the dsRNAs described here (data not
shown). Lastly, elevated phosphorylation of eIF-2α  has
been used as a diagnostic marker of IFN response [30].
We, therefore, examined the phosphorylation status of
eIF-2α  in A549 cells following transfection with these dsR-
NAs. Results (Fig. 5, bottom panel) showed no increase in
phosphorylation. In positive controls, A549 cell treated
with calcium mobilizers (thapsigargin or A23178) did in-
crease eIF-2 phosphorylation, as has been shown earlier
[30]. These results provide the first direct evidence that the
21-nt long double-stranded siRNAs fail to trigger interfer-
on response in mammalian cells, and hence, can be used
as specific antiviral agents.
Discussion
In this communication, we establish 21-nucleotide long
double-stranded interfering RNA as a viable tool to ablate
specific cytoplasmic RNAs, as exemplified by the mRNAs
of a RNA virus. The major findings are: (i) The ablation is
highly efficient: nanomolar concentrations of dsRNA can
lead to a 10–20 fold reduction of the corresponding pro-
tein. The two RSV mRNAs that we have targeted here,
namely P and F, are relatively abundant viral mRNAs. In
fact, they respectively represent the 4th and 5th most abun-
dant viral mRNAs in the infected cell. Thus, we predict
that an even lower concentration of dsRNA, perhaps in
the sub-nanomolar range, might be able to destroy NNR
viral mRNAs that are rarer, such as those of RSV M2 and L
proteins. This is currently being tested. It is to be noted
that a chemical is generally considered a promising phar-
maceutical if it is effective at sub-micromolar concentra-
tions, (ii) The effect is highly specific: dsRNA against one
viral mRNA did not affect other viral mRNAs or the cellu-
lar genes tested here. In this regard, dsRNA generally sur-
passes the standard antisense technology based on
oligodeoxynucleotides (ODNs), whose specificity has of-
ten been debated. Moreover, since the most potent anti-
sense ODNs rely on the degradation of target RNA by
RNase H [31], which is a predominantly nuclear enzyme,
this mechanism is not available to RNA viruses that are
strictly cytoplasmic. (iii) Lack of interferon response: We
provide direct experimental evidence that the 21-nt dsR-
NA does not trigger an IFN response, which is an advan-
tage because an IFN response would have caused a general
and non-specific inhibition of all cap-dependent transla-
tion [5]. (iv) Regulation any time: Although we have not
tested this specifically, one can, in principle, transfect the
virus-infected cell with dsRNA at any time point during in-
fection. This will allow ablation of a specific protein at dif-
ferent times in infection and allow one to determine if the
same "mutation" may have early and late phenotypes. In
addition, this will allow mutational analysis of essential
genes, genetic deletion of which may result in a nonviable
virus. In this regard, the dsRNA technique is akin to a tem-
perature-shift experiment using a temperature-sensitive
mutant virus, however, as implied earlier, conditional le-
thal mutations are not available for the vast majority of vi-
ral genes. (v) Ease of use: The dsRNA approach is relatively
simple to design, and its application in cell culture only
requires the standard transfection technology that already
exists. (vi) Multiple targets: It is also possible to deplete
multiple cellular or viral gene mRNAs in any combina-
tion, either simultaneously or in a temporal order, and
thus ask questions about the interaction between the phe-
notypes. (vii) Normal infection environment: As we have
contended, a major benefit of this approach in viral re-
verse genetics is that one can start with standard wild type
virus (or even a relatively uncharacterized field isolate)
with no requirements of recombinant expression, and
thus, the cellular milieu is only minimally perturbed, if at
all.
Lastly, the lack of effect of the anti-F dsRNA on viral ge-
nome replication deserves special attention. As described
earlier (in the beginning of the Results section), intracel-
lular NNR viral replication generates both negative- and
positive-strand full-length genomic RNA, each of which
should find complementarity to the appropriate strand of
the anti-F dsRNA. In general, genome-length RNAs of
both positive and negative sense could, therefore, be po-
tential targets for RNA interference, resulting in severe in-
hibition of replication. We speculate that the genomic and
antigenomic RNA of NNR viruses escape the onslaught of
dsRNA because they are tightly wrapped with the nucleo-
capsid protein N, which makes them inaccessible to the
dsRNA and/or the RNAi silencing complex (RISC). As
mentioned before, the N-encapsidated genome-length
RNAs are indeed extremely resistant to nucleases, to the
extent that formation of such nuclease-resistant RNA
products is in fact considered a defining criterion for viral
replication in vitro and in vivo[32]. While the resistance of
the viral genomic RNA to dsRNA has important ramifica-
tions for antiviral therapy, it is also clear that the dsRNA
approach cannot be used against cis-acting NNR viral ge-
nomic sequences such as the intergenic regions, for which
the cDNA-based approach will continue to be the method
of choice [16]. It is obvious that a creative combination of
the two techniques will lead to exciting possibilities in the
reverse genetics of RNA viruses and in the antiviral regi-
men.
Conclusions
Properly designed synthetic 21-nucleotide long double-
stranded RNA (dsRNA) molecules can effectively and spe-
cifically abrogate translation of target RNAs without acti-
vating a general interferon response. When applied
against mRNAs of cytoplasmic RNA viruses, the dsRNAsBMC Microbiology 2001, 1 http://www.biomedcentral.com/1471-2180/1/34
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caused degradation of the specific viral mRNA and result-
ant ablation of the specific viral protein. The technique is
quick, simple, and can be used against wild type RNA vi-
ruses in standard tissue culture at any point in the infec-
tion cycle. Post-transcriptional gene silencing by such
dsRNA molecules should facilitate the reverse genetics
and functional genomics of RNA genomes.
Materials and methods
Double-stranded RNA
The following dsRNA sequences with 3'-dT extensions
were synthesized against RSV P, RSV F, and cellular lamin
A/C mRNA sequences (Accession numbers Ml1486,
M22643, and X03444, respectively), following the design
recommendations of Tuschl and coworkers [2]:
P: 5' CGAUAAUAUaACUGCAAGATT 3'
3' TTGCUAUUAUAuUGACGUUCU 5'
F: 5' UGCUGUAACAGAAUUGCAGTT 3'
3' TTACGACAUUGUCUUAACGUC 5'
Lamin: 5' CUGGACUUCCAGAAGAACATT 3'
3' TTGACCUGAAGGUCUUCUUGU 5'
The two T's at the 3'-end of all RNAs were 2'-deoxythymi-
dines. The dT residues most likely provided stability
against RNases [2], since they produced a more reproduc-
ible and sustained effect at a substantially lower concen-
tration, compared to RNAs that contained all
ribonucleotides but an otherwise identical sequence (data
not shown). All oligonucleotide were synthesized by
Dharmacon Research (Lafayette, CO) using their recom-
mended 2'-ACE protection chemistry, and then gel-puri-
fied. Deprotection of the RNA and hybridization of the
two strands were carried out according to the manufactur-
er's protocol. In the mutant dsRNA (for P), the lowercase
a-u base pair was changed to g-c (see Results).
Transfection with dsRNA and RSV infection
The dsRNAs were introduced in cells essentially as de-
scribed [2]. Briefly, A549 cells were propagated in stand-
ard MEM (Life Technologies) supplemented with 10%
fetal bovine serum (FBS) and penicillin-streptomycin.
Twenty-four h before transfection, cells were trypsinized
and transferred to 12-well plates. Transfection with dsR-
NAs was carried out with OligofectAMINE Reagent (Life
Technologies) in OPTIMEM I (Life Technologies) as de-
scribed by the manufacturer for adherent cell lines. Indi-
cated amounts of dsRNA, formulated into liposomes,
were applied per well, and the final volume was 500 µl per
well. Cells were incubated for 6 h after transfection, and
t h e n  i n f e c t e d  w i t h  R S V  L o n g  s t r a i n  a t  a n  m . o . i .  o f  4
[17,33], and FBS was added back to 1% to supplement the
growth of the virus. A second transfection was performed
after 5 h of infection and FBS was again restored to 1% in
12 h after second transfection. At 40 to 48 h after the first
transfection, cells were photographed, or processed for
immunostaining (see below), RNA isolation, or immuno-
blot, as and where indicated.
Indirect immunofluorescence
Rabbit anti-F antibody was raised against a synthetic pep-
tide, and was a kind gift from Dr. James E. Crowe, Jr. (Van-
derbilt University, TN). Rabbit polyclonal antibody
against RSV-P protein has been described [21]. Indirect
immunofluorescence and nuclear staining with DAPI was
performed essentially as described previously [33]. A549
cells in monolayer, grown on cover slips, were washed in
PBS and fixed in ice-cold 10% trichloracetic acid for 15
min, followed by successive washes in cold 70%, 90% and
absolute ethanol for 3 min each. After one more PBS
washing, the fixed cells were incubated for 45 min at
room temperature with anti-P or anti-F protein antibody
in PBS. Thereafter, cells were washed three times for 5 min
in PBS and incubated for 45 min at room temperature
with TRITC- or FITC-conjugated anti-rabbit IgG secondary
antibody (Sigma) diluted 1:75. Nonspecific binding was
eliminated by three washes in PBS. Where mentioned, nu-
clei were stained with DAPI (Sigma) after the final PBS
wash. Cells were visualized and the images digitally cap-
tured in an Olympus BMAX Epifluorescence microscope
using a 100×  oil-immersion objective and appropriate fil-
ters [12,33].
Ex vivo phosphorylation assay
Metabolic labeling of cells and immunoprecipitation was
performed essentially as described previously [21,30]. In
brief, confluent monolayers of A549 cells were transfected
with appropriate dsRNA (at 20 nM final) as described
above, and at 8 hr post-transfection, were washed with a
phosphate-free buffer (120 mM NaCl, 5 mM KCl, 1.5 mM
MgCl2, 0.25 mM CaCl2, 25 mM NaHCO3, 20 mM HEPES
[pH 7.4]) and labeled with 32P-orthophosphate (500 µCi/
ml) (Amersham) in Dulbecco-modified Eagle MEM lack-
ing both phosphate and pyruvate. Where mentioned,
thapsigargin or A23178 was used at final concentrations
of 100 nM, and was added to the cells 15 min before ad-
dition of the 32P-containing medium containing the same
concentration of the drugs. After a 1 h labeling period, all
cells were washed with phosphate-buffered saline without
Ca2+ and Mg2+ and disrupted as described previously to
obtain the total lysate. The eIF-2 was precipitated with a
polyclonal antibody against human eIF-2α  (C-20) (Santa
Cruz Biotech) in the presence of protein G-Sepharose
(Amersham) for 1 h at 10°C, and then processed as de-
scribed previously [21]. The immunoprecipitates wereBMC Microbiology 2001, 1 http://www.biomedcentral.com/1471-2180/1/34
Page 10 of 11
(page number not for citation purposes)
subjected to SDS-PAGE followed by autoradiography to
examine eIF-2 phosphorylation.
To monitor total eIF-2α  in the cell, a parallel A549 mon-
olayer was treated identically except that the labeled or-
thophosphate was omitted. Portions of the total cell lysate
were analyzed by SDS-PAGE followed by immunoblot
with anti-eIF-2α  antibody. All immunoblots (Western
blots) were performed essentially as described [17]. Thap-
sigargin and A23178 were from Sigma-Aldrich.
Reverse transcription-PCR (RT-PCR)
Quantitation of specific mRNAs by RT-PCR was done es-
sentially as described [34]. Briefly, total RNA was isolated
from trypsinized cell monolayers using the Quickprep Mi-
cro™ mRNA purification kit from Pharmacia Biotech (Pis-
cataway, NJ). Equal amounts of total RNA were subjected
to reverse transcription using the C. therm. RT system (Ro-
che Molecular Biochemicals, Indianapolis, IN) at 65°C for
1 hr in the presence of 5 units of RNasin (Promega), fol-
lowed by PCR through increasing number of cycles. The
primers were based on RSV (Acc# M74568) and actin
(X00351) sequences, and are as follows (sense and anti-
sense, respectively):
P: 5'CCCTTTTCTAAACTATACAAAGAAACC3' and
5'AGCAGATGTAGGTCCTGCACTTG3';
F: 5'AGTGTAATGGAACAGATGCCAAGG3' and
5'GCAGGACCTTAGATACAGCAGTG3';
RSV genomic RNA:
5'AATGACCAATTATATGAATCAATTATCTG3' and
5'GTTGACCAGGAATGTAAATGTGGC3';
β -actin: 5'CCTCACCCTGAAGTACCCCATC3' and 
5'GCCGTGGTGGTGAAGCTGTAGC3'. The RT-PCR prod-
ucts were 198, 274, 307, and 420 bp long, respectively, for
these mRNAs. The amount of RNA was optimized for the
individual genes, and PCR samples were withdrawn at 20,
22, 24, and 26 cycles of amplification and analyzed by
standard agarose gel electrophoresis followed by ethid-
ium bromide staining.
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